The value of genomic sequencing in complex pediatric neurological disorders: a discrete choice experiment
暂无分享,去创建一个
[1] J. Christodoulou,et al. The personal utility and uptake of genomic sequencing in pediatric and adult conditions: eliciting societal preferences with three discrete choice experiments , 2020, Genetics in Medicine.
[2] J. Braithwaite,et al. Clinical genomic testing: what matters to key stakeholders? , 2020, European Journal of Human Genetics.
[3] C. Patch,et al. Parents’ motivations, concerns and understanding of genome sequencing: a qualitative interview study , 2020, European Journal of Human Genetics.
[4] S. Rasmussen,et al. Exome sequencing: value is in the eye of the beholder , 2019, Genetics in Medicine.
[5] D. Veenstra,et al. Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study , 2019, PharmacoEconomics.
[6] K. Boycott,et al. The value of diagnostic testing for parents of children with rare genetic diseases , 2019, Genetics in Medicine.
[7] S. Scherer,et al. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders , 2019, Genetics in Medicine.
[8] Alan R. Ellis,et al. Discrete Choice Experiments in Health Economics: Past, Present and Future , 2018, PharmacoEconomics.
[9] Deirdre Weymann,et al. Valuation of Health and Nonhealth Outcomes from Next-Generation Sequencing: Approaches, Challenges, and Solutions. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[10] Kathryn A Phillips,et al. Themed Section: Assesing the Value of Next-Generation Sequencing Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions , 2018 .
[11] S. Kingsmore,et al. Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases , 2018, npj Genomic Medicine.
[12] Deirdre Weymann,et al. Patient preferences for massively parallel sequencing genetic testing of colorectal cancer risk: a discrete choice experiment , 2018, European Journal of Human Genetics.
[13] Peter Vickerman,et al. How well do discrete choice experiments predict health choices? A systematic review and meta-analysis of external validity , 2018, The European Journal of Health Economics.
[14] M. T. Nguyen,et al. Diagnosis of rare diseases under focus: impacts for Canadian patients , 2017, Journal of Community Genetics.
[15] Gert Jan van der Wilt,et al. A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology , 2017, Genetics in Medicine.
[16] J. Kohler,et al. Personal utility in genomic testing: a systematic literature review , 2017, European Journal of Human Genetics.
[17] Andrew T. Collins,et al. On determining priors for the generation of efficient stated choice experimental designs , 2016 .
[18] Y. Bombard,et al. How do women trade-off benefits and risks in chemotherapy treatment decisions based on gene expression profiling for early-stage breast cancer? A discrete choice experiment , 2016, BMJ Open.
[19] A. Schuh,et al. Patients’ Preferences for Genomic Diagnostic Testing in Chronic Lymphocytic Leukaemia: A Discrete Choice Experiment , 2016, The Patient - Patient-Centered Outcomes Research.
[20] J. Rivière,et al. Diagnostic odyssey in severe neurodevelopmental disorders: toward clinical whole‐exome sequencing as a first‐line diagnostic test , 2016, Clinical genetics.
[21] John M. Rose,et al. Applied Choice Analysis , 2015 .
[22] E. Estrella,et al. “Is it Going to Hurt?”: The Impact of the Diagnostic Odyssey on Children and Their Families , 2015, Journal of Genetic Counseling.
[23] David Veenstra,et al. Societal preferences for the return of incidental findings from clinical genomic sequencing: a discrete-choice experiment , 2015, Canadian Medical Association Journal.
[24] Xuan Yuan,et al. Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders , 2014, Science Translational Medicine.
[25] Siddharth Srivastava,et al. Clinical whole exome sequencing in child neurology practice , 2014, Annals of neurology.
[26] David L Veenstra,et al. The economics of genomic medicine: insights from the IOM Roundtable on Translating Genomic-Based Research for Health. , 2013, JAMA.
[27] John M. Rose,et al. Sample size requirements for stated choice experiments , 2013 .
[28] Ray B. Jones,et al. Living without a diagnosis: the parental experience. , 2010, Genetic testing and molecular biomarkers.
[29] Carol A. Marra,et al. Valuing the benefit of diagnostic testing for genetic causes of idiopathic developmental disability: willingness to pay from families of affected children , 2009, Clinical genetics.
[30] K. Payne,et al. Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis , 2008, Genetics in Medicine.
[31] Julie Ratcliffe,et al. Measuring and valuing health benefits for economic evaluation in adolescence: an assessment of the practicality and validity of the child health utility 9D in the Australian adolescent population. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[32] Joanna Coast,et al. Developing attributes and levels for discrete choice experiments using qualitative methods , 2007, Journal of health services research & policy.
[33] Joel R. Evans,et al. The value of online surveys , 2005, Internet Res..
[34] David A. Hensher,et al. A latent class model for discrete choice analysis: contrasts with mixed logit , 2003 .
[35] K. Small,et al. Applied Welfare Economics with Discrete Choice Models , 1979 .
[36] Deborah Marshall,et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[37] Peter Goos,et al. Bayesian optimal designs for discrete choice experiments with partial profiles , 2011 .
[38] Mandy Ryan,et al. Using discrete choice experiments to value health and health care , 2008 .